🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing globally, with figures suggesting over 82 million new cases per year. Notably increased rates are seen in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices currently available.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization marks a major breakthrough in the management of highly resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Results and Worldwide Availability

According to findings published in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This establishes an equal footing with the existing first-line therapy, which uses a dual-drug approach. The study involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals on the front lines have expressed optimism. Access to a easy-to-administer therapy of this kind is described as a "game-changer" for public health efforts. This is deemed crucial to alleviate the strain of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.